Hexokinase-2 bound to mitochondria: Cancer's stygian link to the “Warburg effect” and a pivotal target for effective therapy

This publication has 60 references indexed in Scilit:

• Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
  British Journal of Cancer, 2008
• Causes and Consequences of Increased Glucose Metabolism of Cancers
  Journal of Nuclear Medicine, 2008
• Hexokinase II Detachment from Mitochondria Triggers Apoptosis through the Permeability Transition Pore Independent of Voltage-Dependent Anion Channels
  PLOS ONE, 2008
• Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death
  Nature Cell Biology, 2007
• Lactate and malignant tumors: A therapeutic target at the end stage of glycolysis
  Journal of Bioenergetics and Biomembranes, 2007
• METABOLIC REMODELING OF MALIGNANT GLIOMAS FOR ENHANCED SENSITIZATION DURING RADIOTHERAPY
  Neurosurgery, 2006
• Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria
  Oncogene, 2006
• Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP
  Published by Elsevier ,2004
• Glucose catabolism in cancer cells: regulation of the type II hexokinase promoter by glucose and cyclic AMP
  FEBS Letters, 1996
• Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma
  Biochemical and Biophysical Research Communications, 1985